News

A recent study identified limitations in the Expanded Disability Status Score scale's ability to capture full disability spectrum in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-antibody-associated disease.

The director of the Weill Cornell Women’s Brain Initiative discussed emerging research that highlight the significant impact of sex hormones on women's brain health, and how it influences conditions like Alzheimer disease. [WATCH TIME: 8 minutes]

After 6 months of treatment, nearly half of the small-scale cohort demonstrated enhancements on the Unified MSA Rating Scale, an assessment of activities of daily living.

The neurosurgeon in the department of neurology at Allegheny Health Network talked about the increasing prevalence of chronic pain as the population ages and the treatment options available to patients to provide relief. [WATCH TIME: 5 minutes]

The neurologist and clerkship director at the University of Connecticut provided perspective on the developing role of clerkship directors and the value they provide to neurology departments.

A recent study revealed that pediatric patients with Duchenne and Becker muscular dystrophy have low rates of corticosteroid use.

The neurologist and director of movement disorder neurology at the Marcus Neuroscience Institute discussed how the Syn-One test utilizes alpha-synuclein and what this biomarker adds to the diagnosis of Parkinson disease. [WATCH TIME: 3 minutes]

Additional interim clinical study results comprising 6- and 12-months of treatment data on multiple patients, is expected to be readout in the first quarter of 2025.

The assistant professor at Hunter College talked about how to effectively diagnose and treat multiple sclerosis through localization and active listening of the patient's history and symptoms. [WATCH TIME: 7 minutes]

David Cooper, MD, chief medical officer at AviadoBio, provided insight on a new study assessing AVB-101, an investigational gene therapy, as a potential treatment for patients with frontotemporal dementia.

Secondary symptoms of PD can be as debilitating as the primary motor symptoms, often leading to increased disability, reduced independence, and a higher burden on caregivers.

The significant association between heavy alcohol consumption and young-onset cryptogenic ischemic stroke remained after adjusting for demographics and for further vascular risk factors.

The associate vice president of research at National MS Society talked about proactive and early referral to rehabilitation services to effectively manage multiple sclerosis symptoms from the outset. [WATCH TIME: 4 minutes]

Brivaracetam was largely well tolerated and shown to be effective for a proportion of patients with intellectual disability, indicated by similar responses across different levels of intellectual disability severity.

The neurologist and assistant professor at Boston University Medical Center provided forward thoughts on improving the diagnosis of milder, asymptomatic cases of cerebral amyloid angiopathy. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Intravenous methylprednisolone combined with plasma exchange/immunoadsorption achieved better and continuous improvement than IVMP alone

The pediatric epileptologist at Children's Hospital Colorado talked about a comprehensive review of various studies assessing fenfluramine in severe seizures associated with developmental and epileptic encephalopathies. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending July 20, 2024. [WATCH TIME: 4 minutes]

Neurology News Network. for the week ending July 13, 2024. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on multiple system atrophy.

The behavioral neurologist at NYU Langone Health and chief medical officer at Isaac Health shared his reaction to the recent approval of donanemab for patients with Alzheimer disease. [WATCH TIME: 7 minutes]

Following the positive data, NeuroSense intends to submit 12-month results to the FDA for regulatory discussions on future path.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 12, 2024.

The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals provided clinical insight on a new study evaluating the effect of switching from high- to low-sodium oxybate on blood pressure. [WATCH TIME: 4 minutes]

In a phase 2 trial, the agent met its primary end point of safety, with slowing of disease worsening in patients with mild AD.

The director of the Weill Cornell Women’s Brain Initiative shared her clinical insights into how menopause affects women's brain health, emphasizing the importance of midlife prevention strategies for Alzheimer disease. [WATCH TIME: 10 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sameea Husain-Wilson, DO. [LISTEN TIME: 19 minutes]

A summary of key components of the current MAGNIMS-CMSC-NAIMS consensus recommendations led by experts on the use of MRI in multiple sclerosis for busy clinicians.

Recruitment has begun for Part C of the study, with topline data from this part of the trial expected to report in Q2 2025.